HDAC9 and breast carcinoma: The epi-drugs in use, such as decitabine (a DNMT inhibitor) and Trichostatin A (HDAC inhibitor), against breast cancer, lung cancer, etc., show lack of specificity and serious side effects; therefore, a quest for safer drug candidates is warranted [9,12].